Three drugs targeting the NO-sGC-cGMP pathway are approved for the treatment of PAH: two phosphodiesterase-5 inhibitors (PDE-5is), sildenafil and tadalafil, and the sGC stimulator riociguat (Aaron and Roham, 2013; Ataya et al., 2016; Pulido et al., 2016; Barnes et al., 2019). Here, SGCB is linked to pulmonary arterial hypertension.